News & Insights

Enhanced strategic consultation and new products like Medicare Predictive Model and Enrollment Capabilities are changing Prime’s government programs and delivering better access and costs to members

Care Management feature offers holistic assessment that helps support members by mitigating fraud, waste and abuse and patient safety concerns

Prime’s Special Investigations Unit is specially trained to protect patients and providers throughout the health care continuum

Jon Bunch, assistant vice president of customer experience and member operations, shares insights from event focused on flexible work experience

Joseph Leach, M.D., senior vice president and chief medical officer at Prime Therapeutics/Magellan Rx Management, shares more about the RTBC electronic prescription decision support tool

Pat Gleason, assistant vice president, health outcomes, and David Eckwright, senior director, clinical project and program management, share an overview of Prime’s data and insights slated for this week. 

From new treatment options for dry eye disease to type 2 diabetes, here are a few of the top U.S. Food and Drug Administration drug decisions expected this year

In the U.S. Food and Drug Administration (FDA)’s latest annual report of drug approvals, the agency shared it approved a total of 46 novel drugs in 2025. Here’s how that stacks up against years prior, and what that might mean for the year ahead.

Abby Kim, PharmD, BCOP, is a senior director, clinical strategy and oncology specialty solutions, shares key takeaways from the American Journal of Managed Care (AJMC) forum, “Bridging evidence and access in advanced small cell lung cancer.”  

Understanding the patient journey and leveraging trend insights to manage high-cost specialty drugs on the medical benefit

Maryam Tabatabai, PharmD, associate vice president of clinical information, offers predictions about forthcoming drug approvals, the latest on a new voucher pilot, updated biosimilar guidance and more

A strategic deep dive into the latest trend report from Prime Therapeutics reveals how oncology spend is evolving across benefits and what it means for cancer care management